Moody’s and S&P Assign Investment-Grade Ratings to Sun Pharma
Sun Pharmaceutical Industries Ltd · Others (Uncategorized) · 09 Sept 2026, 2:08 am
Moody’s and S&P Assign Investment-Grade Ratings to Sun Pharma On 8th Sep'26, Moody's and S&P Global assigned Baa1 and preliminary BBB+ long-term issuer ratings, respectively, to Sun Pharma, both with a Stable outlook. The ratings incorporate Sun Pharma’s planned $11.75bn acquisition of Organon, expected to close by early 2027. S&P expects the deal to double revenue to ~INR 1.3tn (~$14bn) by FY28, while Moody's anticipates $350m in cost synergies. Post-acquisition leverage will temporarily spike to 1.8x–3.0x, but robust cash flow is projected to reduce net debt-to-EBITDA toward 1.5x within 18–24 months.
Original exchange filing (PDF)
More announcements from Sun Pharmaceutical Industries Ltd
- Intimation of Schedule of Analyst/Institutional Investor Meeting · 05 Nov 2026
- Q2FY27 Earnings Call Transcript · 05 Nov 2026
- Clarification regarding news report relating to the Company''s Assam facility · 03 Nov 2026
- The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on November 2, 2026, with reference to news appeared in https://www.thehindu.com/ dated October 30, 2026 quoting .... · 02 Nov 2026
- Completion and results of postal ballot dated 01 October 2026 · 01 Nov 2026
- Q2FY27- Investor Call Audio Recording · 31 Oct 2026
- Board Meeting Outcome - Conclusion · 30 Oct 2026
- Unaudited Financial Results for the quarter and half year ended 30 September 2026 · 30 Oct 2026
